Revolutionary Autoinjector Pushes the Limits of High Viscosity Drug Delivery
News Apr 18, 2013
Oval is a cutting-edge autoinjector company based in Cambridge UK. Their autoinjector technology solves currently unsolvable problems in the industry for drug containment and for the end user. Oval are highly focussed and agile, and it is therefore not surprising that they are proving to be a global success and are continuously growing their team.
The automatic delivery of high viscosity drugs is an important milestone for injection delivery, as there is currently no-known automatic injection device, with a needle, on the market which can deliver these viscosities. Viscosity has been a huge problem for many biopharmaceutical formulators as many biologics are very viscous. There has been no effective way of delivering high viscosity drugs through a prefilled syringe, without extreme pain to the patient (due a large needle bore) and physical discomfort, to the care-giver, when administering the injection (due to high injection forces). Not only does this mean that these wonder drugs (often coined magic bullets) can be administered through the Oval device, but they can be administered by the patient in the comfort of their own home.
Oval has wide experimental expertise in the design and testing of primary drug containers, for high viscosity drugs, in their specifically designed laboratories. Testing of pharmaceutical companies’ drugs, to see if they can be delivered in an Oval device, is proving to be a popular service for biopharmaceutical companies. Oval also has a new technology which should enable much higher viscosities (100,000 cPs) to be administered subcutaneously.
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
XenoGesis and Juniper Pharma Services Strengthen AllianceNews
Campanies extend strategic alliance in early drug development services.READ MORE
Quotient Clinical Signs Cocrystal Agreement with NuformixNews
Partnership to evaluate cocrystal formulations using translational pharmaceutics.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018